213620-92-9

Basic information

• Product Name: (Z)-7-[3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester
• CAS NO: 213620-92-9
• Molecular Weight: 439.67
• Mol File: 213620-92-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (Z)-7-[3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-7-[3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester(213620-92-9)
• EPA Substance Registry System: (Z)-7-[3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester(213620-92-9)

Safety Data

• Hazardous Substances Data: 213620-92-9(Hazardous Substances Data)

Upstream product

• 198132-20-6 [3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-pyridin-3-yl-methanol 
• 81168-11-8 3-(((tert-butyldimethylsilyl)oxy)methyl)benzaldehyde 
• 81805-53-0 3-(tert-Butyldimethylsiloxymethyl)benzyl Alcohol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 626-18-6 1,3-dimethanol benzene 
• 50889-29-7 (5-carboxypentyl)triphenylphosphonium bromide 
• 160694-15-5 [3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-pyridin-3-yl-methanone 
• 186581-53-3 diazomethane 

Downstream Products

• 213621-07-9 (Z)-7-{3-[(S)-4-(4-Cyclohexyl-butylcarbamoyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 213621-02-4 (Z)-7-{3-[(S)-1-(4-Cyclohexyl-butylcarbamoyl)-2-hydroxy-ethylcarbamoyl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 213620-97-4 3-((Z)-6-Methoxycarbonyl-1-pyridin-3-yl-hex-1-enyl)-benzoic acid 

Relevant articles and documents

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives

Synthesis and initial in vitro evaluation of a novel series of phenyl oxazole derivatives are described. An SAR study of the novel dual-acting TRA/TSI agent has revealed that the lipophilicity of the oxazole amide substituents greatly influences the TRA activity but not the TSI. The chain length of the alkenoic acid side chain affects both TRA and TSI. The optimal chain length for the combined activities was found to be n = 4 (heptenoic acid).